Radovich Peter's Form 4 filing
Mirum Pharmaceuticals, Inc. (MIRM) · filed Mar 17, 2026
- Accession no.
- 0001650131-26-000010
- Filed
- Mar 17, 2026
- Trade date
- Mar 15-16, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.52M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Radovich PeterCIK 0001650131 | Officer (PRESIDENT AND COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2026 | Common Stock | MOption exerciseAcquired | +7,220 | –F1 | – | 33,787 | Direct | |
| Mar 15, 2026 | Common Stock | MOption exerciseAcquired | +23,000 | –F1 | – | 56,787 | Direct | |
| Mar 16, 2026 | Common Stock | SSaleDisposed | −16,515 | $91.98 | −$1,519,049.7 | 40,272 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2026 | Common Stock | MOption exerciseDisposed | −7,220 | $0.00 | $0 | 0 | Direct | |
| Mar 15, 2026 | Common Stock | MOption exerciseDisposed | −23,000 | $0.00 | $0 | 11,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Referenced by the price of 2 transactions in Table I.